- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Pfizer is making another acquisition.
The acquisition of Medivation gives the pharma giant a top-selling oncology drug and an immediate profit boost.
Pfizer buys antibiotics business from AstraZeneca; Tesla unveils Model S version that can go 300 miles on a single charge; U.S. stock futures rise slightly.
Medivation's (MDVN) stock rating was cut by several firms on Tuesday morning after the company agreed to be acquired by Pfizer (PFE) for $14 billion yesterday.